HomeCompareMNMD vs PLD

MNMD vs PLD: Dividend Comparison 2026

MNMD yields 10.58% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.46M in total portfolio value· pulled ahead in Year 4
10 years
MNMD
MNMD
● Live price
10.58%
Share price
$18.91
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.2K
Annual income
$2,053.05
Full MNMD calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — MNMD vs PLD

📍 PLD pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNMDPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNMD + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNMD pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNMD
Annual income on $10K today (after 15% tax)
$899.00/yr
After 10yr DRIP, annual income (after tax)
$1,745.09/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,466,225.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNMD + PLD for your $10,000?

MNMD: 50%PLD: 50%
100% PLD50/50100% MNMD
Portfolio after 10yr
$3.27M
Annual income
$2,629,244.61/yr
Blended yield
80.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

MNMD
Analyst Ratings
1
Buy
Consensus: Buy
Price Target
$28.00
+48.1% upside vs current
Range: $28.00 — $28.00
Altman Z
5.2
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNMD buys
0
PLD buys
0
No recent congressional trades found for MNMD or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNMDPLD
Forward yield10.58%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$40.2K$6.50M
Annual income after 10y$2,053.05$5,256,436.18
Total dividends collected$15.5K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$28.00$136.00

Year-by-year: MNMD vs PLD ($10,000, DRIP)

YearMNMD PortfolioMNMD Income/yrPLD PortfolioPLD Income/yrGap
1$11,758$1,057.64$11,255$555.24+$503.00MNMD
2$13,743$1,162.18$13,062$1,018.59+$681.00MNMD
3$15,974$1,269.54$15,903$1,926.67+$71.00MNMD
4← crossover$18,472$1,379.15$20,839$3,823.32$2.4KPLD
5$21,255$1,490.43$30,464$8,166.08$9.2KPLD
6$24,346$1,602.82$52,054$19,457.30$27.7KPLD
7$27,766$1,715.78$109,886$54,188.93$82.1KPLD
8$31,538$1,828.79$304,030$186,451.18$272.5KPLD
9$35,687$1,941.36$1,166,125$840,813.32$1.13MPLD
10$40,239$2,053.05$6,504,190$5,256,436.18$6.46MPLD

MNMD vs PLD: Complete Analysis 2026

MNMDStock

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Full MNMD Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this MNMD vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNMD vs SCHDMNMD vs JEPIMNMD vs OMNMD vs KOMNMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.